Published in N Engl J Med on October 03, 1991
The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol (2005) 3.09
Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. J Physiol (2004) 2.75
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci U S A (1995) 2.40
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension (2008) 1.67
Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol (1998) 1.53
Plasma endothelin-1 levels in Behçet's disease. Clin Rheumatol (1997) 1.48
Tadalafil treatment had a modest effect on endothelial cell damage and repair ability markers in men with erectile dysfunction and vascular risk. Asian J Androl (2014) 1.39
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Endothelin-1 activates a Ca2+-permeable cation channel with TRPC3 and TRPC7 properties in rabbit coronary artery myocytes. J Physiol (2007) 1.26
Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med (2010) 1.25
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol (2000) 1.18
Glyceraldehyde-3-phosphate dehydrogenase regulates endothelin-1 expression by a novel, redox-sensitive mechanism involving mRNA stability. Mol Cell Biol (2008) 1.15
Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A (1995) 1.11
Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation (2010) 1.08
Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk. Proc Natl Acad Sci U S A (2011) 1.08
Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol (1999) 1.05
CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol (2004) 1.02
The cardiovascular physiology and pharmacology of endothelin-1. Adv Pharmacol (2010) 1.01
Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J (1995) 1.01
The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol (2004) 0.99
Endothelium-derived endothelin-1. Pflugers Arch (2009) 0.97
Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults. Am J Physiol Regul Integr Comp Physiol (2009) 0.95
Retinal vein occlusions: The potential impact of a dysregulation of the retinal veins. EPMA J (2010) 0.95
Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol (2013) 0.92
Endothelin receptors in human coronary artery and aorta. Br J Pharmacol (1996) 0.92
Thermotherapy reduces blood pressure and circulating endothelin-1 concentration and enhances leg blood flow in patients with symptomatic peripheral artery disease. Am J Physiol Regul Integr Comp Physiol (2016) 0.91
Role of endothelin-1 and the ETA receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol (1995) 0.90
Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol (1995) 0.89
Tendency to angry rumination predicts stress-provoked endothelin-1 increase in patients with coronary artery disease. Psychosom Med (2010) 0.89
Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol (1996) 0.89
Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol (2001) 0.89
Depression predicts elevated endothelin-1 in patients with coronary artery disease. Psychosom Med (2010) 0.88
Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol (2010) 0.88
Nitric oxide function in atherosclerosis. Mediators Inflamm (1997) 0.87
The effect of the ETA receptor antagonist, FR 139317, on [125I]-ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol (1994) 0.87
Suppression of endothelin-1-induced mitogenic responses of human aortic smooth muscle cells by interleukin-1 beta. J Clin Invest (1995) 0.87
Voltage-insensitive Ca2+ channels and Ca2+/calmodulin-dependent protein kinases propagate signals from endothelin-1 receptors to the c-fos promoter. Mol Cell Biol (1996) 0.87
Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest (1996) 0.87
Alterations in nitric oxide and endothelin-1 bioactivity underlie cerebrovascular dysfunction in ApoE-deficient mice. J Cereb Blood Flow Metab (2010) 0.86
Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression. DNA Cell Biol (2009) 0.85
Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol (1999) 0.84
Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion. Br J Pharmacol (2014) 0.84
Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol (2015) 0.83
Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol (1995) 0.83
HIV-1, reactive oxygen species, and vascular complications. Free Radic Biol Med (2012) 0.83
Autonomic contribution to endothelin-1 increase during laboratory anger-recall stress in patients with coronary artery disease. Mol Med (2011) 0.82
Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. Heart Vessels (2010) 0.82
Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms. J Clin Invest (1996) 0.82
Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol (1995) 0.81
Obesity-related inflammation & cardiovascular disease: efficacy of a yoga-based lifestyle intervention. Indian J Med Res (2014) 0.80
Use of isolated ocular arteries in vitro to define the pathology of vascular changes in glaucoma. Br J Ophthalmol (1997) 0.80
Endothelin and endothelium-derived relaxing factor control of basal renovascular tone in hydronephrotic rat kidneys. J Physiol (1993) 0.80
Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. Br J Pharmacol (2006) 0.80
Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat. PLoS One (2017) 0.79
Orphan nuclear receptor Nur77 is a novel negative regulator of endothelin-1 expression in vascular endothelial cells. J Mol Cell Cardiol (2014) 0.78
Endothelial function, endothelin-1, and fibrinogen in young women using the vaginal contraceptive ring. Fertil Steril (2008) 0.78
Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev (2001) 0.78
Expression of endothelial nitric oxide synthase and endothelin-1 in skin tissue from amputated limbs of patients with complex regional pain syndrome. Mediators Inflamm (2008) 0.78
The association of endothelin-1 with markers of oxidative stress in a biethnic South African cohort: the SABPA study. Hypertens Res (2016) 0.77
Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. J Pain Res (2014) 0.77
Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest (1996) 0.77
Comparison of 2 endothelin-receptor antagonists on in vitro responses of equine palmar digital arterial and venous rings to endothelin-1. Can J Vet Res (2006) 0.77
Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries. Br J Pharmacol (1995) 0.76
Further evidence for a role of endothelin-1 (ET-1) in critical limb ischaemia. J Cell Commun Signal (2010) 0.76
Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J (1994) 0.76
High frequency rotational ablation: an alternative in treating coronary artery stenoses and occlusions. Br Heart J (1993) 0.75
Methods for Analysis of Matrix Metalloproteinase Regulation of Neutrophil-Endothelial Cell Adhesion. Biol Proced Online (2002) 0.75
Protective effects of tanshinone ⅡA on endothelial progenitor cells injured by tumor necrosis factor-α. Mol Med Rep (2015) 0.75
Role of endothelin in microvascular dysfunction following percutaneous coronary intervention for non-ST elevation acute coronary syndromes: a single-centre randomised controlled trial. Open Heart (2016) 0.75
Minimally modified LDL upregulates endothelin type A receptors in rat coronary arterial smooth muscle cells. Mediators Inflamm (2013) 0.75
Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells. Br J Pharmacol (2016) 0.75
Vascular function and Endothelin-1: Tipping the Balance between Vasodilation and Vasoconstriction. J Appl Physiol (1985) (2016) 0.75
The Role of the Endothelin System in the Vascular Dysregulation Involved in Retinitis Pigmentosa. J Ophthalmol (2015) 0.75
Dihydropyridine calcium channel blockers and renal disease. Hypertens Res (2016) 0.75
Aerobic vs anaerobic exercise training effects on the cardiovascular system. World J Cardiol (2017) 0.75
Plasma C-terminal pro-endothelin-1 is associated with target-organ damage in African Americans with hypertension. Am J Hypertens (2010) 0.75
Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev (2001) 0.75
Comparison of Serum Levels of Endothelin-1 in Chronic Periodontitis Patients Before and After Treatment. J Clin Diagn Res (2017) 0.75
Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med (1997) 9.36
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med (1992) 3.53
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet (1993) 3.34
Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg (1992) 3.05
Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. J Vasc Surg (2001) 2.43
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med (1989) 2.35
Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 2.08
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res (1993) 1.98
Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc (1995) 1.98
Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg (1994) 1.86
Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA (1998) 1.81
Natriuretic peptide system in human heart failure. Circulation (1993) 1.79
Ruptured abdominal aortic aneurysms: repair should not be denied. J Vasc Surg (1992) 1.75
Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol (1984) 1.71
Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc (1992) 1.70
Aorto-caval and ilio-iliac arteriovenous fistulae. Am J Surg (1998) 1.70
Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart (2009) 1.69
Replacement of the inferior vena cava for malignancy: an update. J Vasc Surg (2000) 1.66
Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res (1988) 1.58
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation (1990) 1.57
Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest (1989) 1.57
Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. Am J Transplant (2008) 1.56
Endothelin in human congestive heart failure. Circulation (1994) 1.56
Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation (1995) 1.55
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol (1990) 1.55
Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg (1997) 1.54
Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc (1998) 1.53
Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest (1988) 1.53
Real time analysis of the affinity regulation of alpha 4-integrin. The physiologically activated receptor is intermediate in affinity between resting and Mn(2+) or antibody activation. J Biol Chem (2001) 1.51
Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol (1992) 1.50
Aortic fenestration for acute or chronic aortic dissection: an uncommon but effective procedure. J Vasc Surg (2000) 1.46
Arrhythmogenic right ventricular dysplasia masquerading as dilated cardiomyopathy. Am J Cardiol (1999) 1.44
Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol (2001) 1.44
Prayer as therapy. A challenge to both religious belief and professional ethics. The Anglican Working Group in Bioethics. Hastings Cent Rep (2000) 1.42
Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. J Am Coll Cardiol (1990) 1.41
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Myocardial revascularization before abdominal aortic aneurysmorrhaphy: effect of coronary angioplasty. Mayo Clin Proc (1993) 1.40
Inflammatory abdominal aortic aneurysms: a thirty-year review. J Vasc Surg (1985) 1.37
High throughput flow cytometry. Cytometry (2001) 1.36
Reconstruction of the vena cava and of its primary tributaries: a preliminary report. J Vasc Surg (1990) 1.32
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol (1998) 1.32
Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol (1980) 1.31
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc (2001) 1.29
Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol (2000) 1.28
Arterial-esophageal fistulae developing in patients with anomalies of the aortic arch system. Chest (1984) 1.28
Ischemic injury to the spinal cord or lumbosacral plexus after aorto-iliac reconstruction. Am J Surg (1991) 1.27
Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol (1992) 1.27
Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol (1993) 1.26
Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ Res (1999) 1.24
Failing energetics in failing hearts. Curr Cardiol Rep (2000) 1.24
Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol (1992) 1.23
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Inflammatory abdominal aortic aneurysms: a case-control study. J Vasc Surg (1996) 1.23
The limitations of polytetrafluoroethylene in the reconstruction of femoropopliteal and tibial arteries. Surg Gynecol Obstet (1981) 1.22
Adrenomedullin: potential in physiology and pathophysiology. Life Sci (2000) 1.22
Performance of in-line microfluidic mixers in laminar flow for high-throughput flow cytometry. Biotechniques (2002) 1.21
Lymphocyte subset analysis by flow cytometry. Comparison of three different staining techniques and effects of blood storage. J Immunol Methods (1989) 1.21
The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians (1999) 1.20
C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol (1993) 1.19
Ventricular septal rupture complicating acute myocardial infarction: identification of simple and complex types in 53 autopsied hearts. Am J Cardiol (1984) 1.18
Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation (1995) 1.18
Totally laparoscopic aortobifemoral bypass grafting in an experimental model: description of technique with initial surgical results. Ann Vasc Surg (1996) 1.18
Noninvasive evaluation of the swollen extremity: experiences with 190 lymphoscintigraphic examinations. J Vasc Surg (1989) 1.17
Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int (1996) 1.15
Counseling: implementing our knowledge in a hurried and complex world. Am J Prev Med (1999) 1.13
Reconstruction of large veins for nonmalignant venous occlusive disease. J Vasc Surg (1992) 1.12
Isolated renal artery dissection, presentation, evaluation, management, and pathology. Mayo Clin Proc (1982) 1.12
Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens (2000) 1.12
Peripheral venous aneurysms with recurrent pulmonary embolism: report of a case and review of the literature. Cardiovasc Intervent Radiol (1982) 1.10
Influence of coronary artery disease on morbidity and mortality after abdominal aortic aneurysmectomy: a population-based study, 1971-1987. J Am Coll Cardiol (1989) 1.09
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J (1999) 1.09
Surgical management of renal artery aneurysm. Cardiovasc Surg (1993) 1.09
Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail (2000) 1.07
Vena cava replacement for malignant disease: is there a role? Ann Vasc Surg (1993) 1.06
Coarctation of the abdominal aorta: current options in surgical management. Ann Surg (1980) 1.06
Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep (2000) 1.06
Thoracoabdominal aortic aneurysm repair. Analysis of postoperative morbidity. Arch Surg (1988) 1.05
Sulfhydryl regulation of L-selectin shedding: phenylarsine oxide promotes activation-independent L-selectin shedding from leukocytes. J Immunol (2000) 1.05
Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int (1999) 1.05
Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension (2001) 1.05
Intact and altered endothelium in regulation of vasomotion. Circulation (1992) 1.05
Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol (1992) 1.04
Influence of complete revascularization on chronic mesenteric ischemia. Am J Surg (1992) 1.04
Brachiocephalic aneurysm: the case for early recognition and repair. Ann Vasc Surg (1991) 1.04
Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation (1993) 1.03
Risks for renal dysfunction with cardiac angiography. Ann Intern Med (1986) 1.03
C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol (1998) 1.03